Windlas Biotech Reports Unaudited Financial Results for Q2 FY26; Confirms Subsidiary Dissolution
Windlas Biotech Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a profit of 176.53 million Indian Rupees (INR) in the quarter, showing strong performance against prior periods.The Board of Directors approved the financial outcomes, which were reviewed by statutory auditors. These results reflect that the company is no longer preparing consolidated financial statements effective from April 1, 2026, following the dissolution of its wholly owned non-operating subsidiary, Windlas Inc., USA.
Key operational updates detailed in the results include the completion of a share buyback and subsequent dividend payout. The company successfully bought back 470,000 fully paid up equity shares through a Tender Offer route at a price of Rs. 1,000 per share, amounting to INR 470,000 million. A Capital Redemption Reserve equivalent to the nominal value of the bought back shares was created.
The company further noted that shareholders approved an aggregate dividend payout of INR 130.01 million on July 31, 2026, following a proposal made by the Board of Directors in May 2026. During the quarter, the company recognized employee share-based payment expense totaling 71.62 million INR.
Financial Performance Snapshot
The unaudited financial statements for the quarter ended June 30, 2026 are presented below (all amounts in Indian Rupees in millions).| Particulars | Q Ended Jun 30, 2026 | Q Ended Mar 31, 2026 | Q Ended Jun 30, 2025 | Year Ended Mar 31, 2026 |
|---|---|---|---|---|
| Revenue from Operations | 2,480.99 | 2,384.99 | 2,100.90 | 9,040.89 |
| Total Income | 2,532.12 | 2,428.97 | 2,153.29 | 9,218.93 |
| Total Expenses | 2,302.76 | 2,227.35 | 1,920.71 | 8,349.62 |
| Profit before tax | 229.36 | 201.62 | 232.58 | 869.31 |
| Total Tax Expense | 52.83 | 41.46 | 55.93 | 204.96 |
| Profit for the quarter | 176.53 | 160.16 | 176.65 | 664.35 |
| Basic Earnings per share (in Rs.) | 8.46 | 7.60 | 8.43 | 31.59 |
The financial statements reflect that the company maintains a single primarily reportable segment, identified as "Pharmaceuticals," according to Ind-AS 108 on 'Operating Segment'.
WINDLAS Stock Price Movement
Shares of Windlas Biotech Limited tumbled today in post-market trading, shedding 6.99% or ₹61.75 and settling at ₹821.10. The stock recorded a total traded volume of 114,397 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.